$135.99
-1.77[-1.28%]
At close: Apr 26
$135.99
0[0.00%]
After Hours: 4:00PM EDT
Neurocrine Biosciences: Insider buying and selling updated today.
Filing Date | Insider Names | Insider Title | Qty. | Price | Size ($) | Type | Δ Own | Own | Trade Dates | SEC Filing |
---|---|---|---|---|---|---|---|---|---|---|
Apr 17, 2024 | ERIC BENEVICH | CHIEF COMMERCIAL OFFICER | 0 | $107.29 | -$1.03M | SELL-OPTIONS | 0.00% | 40.778K | Apr 15 | View |
Apr 03, 2024 | Ingrid Delaet | CHIEF REGULATORY OFFICER | 0 | $108.16 | -$15.85K | SELL-OPTIONS | 0.00% | 7.507K | Apr 01 | View |
Mar 25, 2024 | Ingrid Delaet | CHIEF REGULATORY OFFICER | 0 | $124.29 | -$207.72K | SELL-OPTIONS | 0.00% | 7.507K | Mar 21 | View |
Mar 15, 2024 | ERIC BENEVICH | CHIEF COMMERCIAL OFFICER | 0 | $110.14 | -$4.39M | SELL-OPTIONS | 0.00% | 40.778K | Mar 14 | View |
Mar 15, 2024 | GEORGE MORROW | DIRECTOR | 0 | $89.60 | -$3.99M | SELL-OPTIONS | 0.00% | 0 | Mar 14 | View |
Mar 15, 2024 | RICHARD POPS | DIRECTOR | 0 | $91.54 | -$2.26M | SELL-OPTIONS | 0.00% | 29.512K | Mar 13 | View |
Mar 15, 2024 | Ingrid Delaet | CHIEF REGULATORY OFFICER | 0 | $123.08 | -$102.36K | SELL-OPTIONS | 0.00% | 7.507K | Mar 13 | View |
Mar 12, 2024 | RICHARD POPS | DIRECTOR | 0 | $91.40 | -$175.11K | SELL-OPTIONS | 0.00% | 29.512K | Mar 08 - Mar 11 | View |
Mar 12, 2024 | Ingrid Delaet | CHIEF REGULATORY OFFICER | 0 | $123.02 | -$68.01K | SELL-OPTIONS | 0.00% | 7.507K | Mar 08 - Mar 11 | View |
Feb 29, 2024 | Ingrid Delaet | CHIEF REGULATORY OFFICER | 0 | $107.18 | -$383.95K | SELL-OPTIONS | 0.00% | 7.507K | Feb 28 - Feb 29 | View |
Feb 29, 2024 | ERIC BENEVICH | CHIEF COMMERCIAL OFFICER | 0 | $94.18 | -$6.08M | SELL-OPTIONS | 0.00% | 40.616K | Feb 28 | View |
Feb 29, 2024 | Leslie Norwalk V | DIRECTOR | 0 | $110.31 | -$405.79K | SELL-OPTIONS | 0.00% | 0 | Feb 27 | View |
Feb 22, 2024 | RICHARD POPS | DIRECTOR | 0 | $72.72 | -$1.79M | SELL-OPTIONS | 0.00% | 29.512K | Feb 20 | View |
Feb 15, 2024 | EIRY ROBERTS | CHIEF MEDICAL OFFICER | -1.114K | $132.96 | -$148.12K | SELL | -4.49% | 23.716K | Feb 13 | View |
Feb 15, 2024 | Jude Onyia | CHIEF SCIENTIFIC OFFICER | -1.432K | $132.94 | -$190.37K | SELL | -9.84% | 13.128K | Feb 13 | View |
Feb 15, 2024 | Darin Lippoldt | CHIEF LEGAL OFFICER | -1.098K | $132.99 | -$146.03K | SELL | -2.69% | 39.74K | Feb 13 | View |
Feb 15, 2024 | CHARLES KEVIN GORMAN | CHIEF EXECUTIVE OFFICER | -2.832K | $133.02 | -$376.70K | SELL | -0.55% | 514.596K | Feb 13 | View |
Feb 15, 2024 | Kyle Gano | CHIEF BUSINESS DEVELOPMENT OFF | -1.352K | $132.89 | -$179.67K | SELL | -0.99% | 135.166K | Feb 13 | View |
Feb 15, 2024 | Ingrid Delaet | CHIEF REGULATORY OFFICER | -716 | $133.03 | -$95.25K | SELL | -8.71% | 7.507K | Feb 13 | View |
Browse insider trades on all stocks.